Neumora discards depression asset, lays off staffers after pair of late-stage flops

Neumora Discontinues Depression Drug, Lays Off 35% After Phase 3 Flops

Neumora Therapeutics is laying off 35% of its workforce and discontinuing its oral drug candidate, navacaprant, for major depressive disorder (MDD) after it failed to meet primary or key secondary endpoints in two Phase 3 studies, KOASTAL-2 and KOASTAL-3. The drug, a kappa opioid receptor (KOR) antagonist, showed no statistically significant improvement in depressive symptoms compared to placebo. This news caused Neumora's stock to drop by nearly 50% in premarket trading. The company is now shifting focus to its earlier-stage pipeline assets.

• Neumora's navacaprant, a KOR antagonist, failed to achieve statistical significance in improving depressive symptoms, as measured by the Montgomery-Asberg Depression Rating Scale, in the Phase 3 KOASTAL-2 and KOASTAL-3 trials. In KOASTAL-2 (over 400 participants), navacaprant's symptom score was similar to placebo, while in KOASTAL-3 (over 400 participants), it was numerically lower than placebo. This follows an earlier failure of KOASTAL-1 in MDD in January 2025.
• Following the trial failures, Neumora announced a significant workforce reduction of 35%, affecting over 30 employees, primarily in R&D. This move is projected to save the company approximately $10 million annually and is expected to occur in the second and third quarters of this year. The news led to a nearly 50% drop in Neumora's stock price in premarket trading, though analysts considered it an overreaction given the high-risk nature of the program.
• With the discontinuation of navacaprant, Neumora is re-focusing on its "promising clinical pipeline." This includes NMRA-511 for Alzheimer’s disease agitation (Phase 1 data expected Q4 this year, Phase 2b by end of 2026), M4 positive allosteric modulator NMRA-898 for schizophrenia (data readout H2 this year), and NLRP3i inhibitor NMRA-215 for obesity (13-week preclinical findings planned). Analysts view this as a "clearing event" for the stock, potentially offering an entry point for investors.

Unpacking Navacaprant's Phase 3 Failures in Major Depressive Disorder

Three recent studies illustrate the breadth of approaches being investigated in MDD, spanning nutritional supplementation, physical intervention, and probiotic therapy. The multicenter, double-blind, placebo-controlled randomized clinical trial of ω-3 fatty acids in pediatric MDD (NCT03167307), conducted across five Swiss child and adolescent psychiatry centers, enrolled 257 youths (mean age 15.7 years) between April 2017 and March 2022. Participants received either 1.5 g/day of ω-3 fatty acids (1 g EPA and 0.5 g DHA, 2:1 ratio) or a medium-chain triglyceride placebo, both combined with standardized psychotherapy, over a 36-week follow-up period. Despite confirmed adherence—evidenced by a mean ω-3 index rise of 4.33% at 12 weeks—the intervention conferred no significant benefit over placebo: adjusted mean CDRS-R difference was 0.77 (95% CI −1.39 to 2.93; P = 0.49), with comparable response and remission rates across timepoints. Seventy-six serious adverse events were reported across 97 participants, including 28 suicide attempts, though none were judged causally related to study medication and no deaths or permanent disabilities occurred.

The 2026 Cochrane systematic review on exercise for depression synthesized 73 RCTs (at least 4,985 participants) comparing exercise to no treatment, inactive controls, or active comparators in adults with MDD. Across 57 trials comparing exercise to no treatment or control, the pooled standardized mean difference (SMD) for depressive symptom reduction was −0.67 (95% CI −0.82 to −0.52; low-certainty evidence), though this attenuated to −0.46 (95% CI −0.88 to −0.04) when restricted to seven methodologically rigorous trials. Notably, exercise showed little to no difference versus psychological therapy (SMD 0.03; 10 trials) or pharmacological treatment (SMD −0.11; 5 trials), with treatment acceptability broadly comparable across modalities. Adverse events were infrequent and included musculoskeletal injuries in the exercise arm and gastrointestinal, sexual, and fatigue-related effects among those receiving sertraline as an active comparator.

A 2026 systematic review and meta-analysis of probiotic monotherapy in unmedicated individuals with depression—registered with PROSPERO (CRD420251015474) and following PRISMA 2020 guidelines—pooled data from six RCTs encompassing 341 randomized participants (169 probiotic, 172 placebo). Probiotic monotherapy was associated with a small but statistically significant reduction in depressive symptoms (SMD = −0.38, 95% CI −0.57 to −0.18; P = 0.0002; I² = 51%). However, the effect did not survive sensitivity analyses that excluded industry-funded trials or studies with adjunctive agents (SMD = −0.21, 95% CI −0.65 to 0.23; P = 0.35), substantially limiting the strength of conclusions. Exploratory subgroup analyses suggested potentially greater benefit in mild-to-moderate depression compared to MDD specifically. Safety findings were reassuring, with only minor adverse events reported and no significant between-group differences, supporting a generally acceptable tolerability profile in unmedicated individuals.

The Challenging Landscape for Kappa Opioid Receptor Antagonists in MDD

Kappa opioid receptor (KOR) antagonism has emerged as a mechanistically differentiated approach to MDD, with navacaprant not alone in this space. Aticaprant — a potent, selective, short-acting KOR antagonist — is the principal comparator drug being trialled for MDD using the same mechanism of action. Both agents operate on the premise that KOR activation drives dysphoria and anhedonia, while antagonism confers antidepressant-like effects, supporting their investigation as novel pharmacotherapies in this indication.

Persistent Challenges and Unmet Needs in Major Depressive Disorder

Despite decades of research, the treatment landscape for Major Depressive Disorder (MDD) remains constrained by high rates of non-response, diagnostic gaps, and a pharmacological toolkit that has seen limited mechanistic innovation over the past 50 years. Approximately 30% of patients are classified as treatment-resistant depression (TRD), and the majority require more than one medication trial before achieving adequate symptom relief — often without reaching full remission.

• High rates of inadequate response: Only around one-third of patients respond to the first pharmacological trial, and up to 30% do not benefit adequately from any available therapeutic intervention, including both pharmacotherapy and psychotherapy. Antidepressant use rarely results in full remission, underscoring a fundamental efficacy ceiling in current standard-of-care options.

• Stagnant pharmacological innovation: Pharmacotherapy has remained the primary treatment modality for MDD, yet its mechanistic underpinnings have changed little over the past five decades. MDD pathophysiology remains incompletely understood, and the lack of validated mechanistic targets continues to impede the development of more effective drug classes.

• Access, stigma, and misdiagnosis barriers: Depression is frequently under-recognized or misdiagnosed in primary care settings, and many patients never receive appropriate treatment. Even when options are available, engagement is hindered by stigma, cost, accessibility constraints, and intolerable side effects — compounding the already significant disability burden.

• Limitations of emerging interventions: Ketamine has demonstrated robust short-term efficacy as the first rapid-acting antidepressant, but long-term safety and durability of response remain uncertain. Electroconvulsive therapy (ECT) retains gold-standard status for TRD yet is chronically underutilized due to limited availability, stigma, and concerns over cognitive side effects. Critically, ECT and ketamine have not been compared in a sufficiently powered head-to-head randomized trial, though the ELEKT-D non-inferiority study (n=400) is designed to address this gap.

• Absence of reliable predictive biomarkers: Single biomarker sets have shown limited predictive power for treatment response, leaving clinician decision-making largely empirical. The integration of pharmacogenomic testing (PGT), therapeutic drug monitoring (TDM), and AI-driven tools represents a promising pathway toward model-informed precision dosing (MIPD), but widespread clinical implementation remains nascent.

• Emerging but unproven mechanistic targets: Novel therapeutic avenues — including selective HDAC1/HDAC2 inhibition for epigenetic modulation of neuroplasticity, neuroimmune pathway targeting for biomarker discovery, and an expanding array of neuromodulation modalities — show early preclinical and clinical promise. However, substantial evidence generation and infrastructure development are required before these approaches can achieve broad clinical adoption or meaningfully reduce the economic burden of MDD on healthcare systems.